Author

Eva Kiessling

University of ZurichORCID 0000-0002-7656-3147Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Antonia Fottner· 1 shared Christian GrimmiD· 1 shared Claudia Matter· 1 shared Cornelia Imsand· 1 shared Diego S. Fajardo· 1 shared Duygu KarademiriD· 1 shared Florian PetersiD· 1 shared Frank BlaseriD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperNeuroscience

Antonia Fottner

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A novel multiplex RNAi therapy simultaneously targets Hif1a and Hif2a to defy retinal degeneration in two models of AMD

Lynn J. A. Ebner, Cornelia Imsand, Duygu Karademir, Florian Peters, Eva Kiessling, Antonia Fottner, Claudia Matter, Diego S. Fajardo, Luca Merolla, Gabriele M Wögenstein, Ioanna Tsioti, Larissa P. Govers, Frank Blaser, Isabelle Meneau, Sanford L. Boye, , Marijana Samardzija

This paper develops a dual-acting RNAi therapy targeting Hif1a and Hif2a to protect retinal cells in AMD models, showing superior efficacy compared to single-target therapies.

Molecular Therapy · Sep 27, 2025Peer-reviewedNeuroscience